Further corroborating the involvement of mast cells driven by IgE in ABPA, treatment with omalizumab (a monoclonal antibody targeting the high-affinity receptor binding site on human IgE and thereby reducing mast cell sensitisation) has been shown to be effective for patients with severe allergic asthma and ABPA (136). This evidence concerns the gene IGHE and allergic asthma.